Orthocell completes CelGro study accelerating dental implant treatments
Thursday, 20 June 2019 Orthocell Ltd (ASX:OCC) has completed the CelGro® single-stage dental implant study designed to assess effectiveness and predictability in accelerating treatment timeframes. The marketing study follows the successful two-stage dental implant trial and market authorisation of CelGro in the European Union for dental bone and soft tissue applications. Study results further validate CelGro as a superior medical device for bone and soft tissue repair and will assist in driving market adoption. “CelGro as the best in class collagen membrane” Orthocell’s managing director Paul Anderson said: “CelGro’s ability to deliver superior bone growth has the potential to revolutionise dental implant techniques and is highly desired by physicians and potential partners. “The latest results provide further evidence that positions CelGro as the best in class collagen membrane.” The 10 patients treated in the marketing study had previously suffered, in some cases for many years, from damaged, missing or diseased teeth. Symptoms prior to treatment included severe irritation, bleeding gums, an inability to chew or eat certain foods and enjoy a normal diet. Treatment completion in four months After surgery with CelGro the impact on patients’ lives was ‘significant’ with patients having successfully generated enough new bone to stabilise their implants and complete treatment in about four months. This is almost half the time of the usual two-stage dental implant treatment. The performance study underpins the compatibility and versality of CelGro as a platform technology and highlights the potential to extend the company’s innovative dental product range. Orthocell is also leveraging the EU regulatory approval and finalising its submission for US regulatory clearance.
Dogs Can Detect Lung Cancer With 97% Accuracy In a new study, researchers used three beagles to sniff out different blood samples. The report can be found in 'The Journal of the American Osteopathic Association.' The dogs were first trained for two months to give signs if they detected cancer from...
Over half of men admit to feeling "embarrassed" about their body hair, new research has found. The fascinating statistic emerged in a survey of 2,000 men which found that 55 percent of all respondents..
Seelos Therapeutics Inc (NASDAQ:SEEL) is one step closer to launching a Phase 2b/3 clinical study for the treatment of Sanfilippo syndrome. The company has filed... Proactive Investors Also reported by •Business Wire